These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 3861248)

  • 1. Phase II study of mitoxantrone, aclarubicin, and diaziquone in the treatment of non-small cell lung carcinoma: an Eastern Cooperative Oncology Group study.
    Ettinger DS; Finkelstein DM; Harper GR; Ruckdeschel JC; Chang AY; Camacho FJ; Marsh JC; Silber R; Wolter JM
    Cancer Treat Rep; 1985 Sep; 69(9):1033-4. PubMed ID: 3861248
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II study of aclarubicin and diaziquone in the treatment of advanced small cell bronchogenic carcinoma (EST 4581): an Eastern Cooperative Oncology Group Study.
    Abeloff MD; Finkelstein DM; Chang AY; Camacho FJ; Creech RH; Ettinger DS
    Cancer Treat Rep; 1985 Apr; 69(4):451-2. PubMed ID: 3857972
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II study of diaziquone in patients with advanced carcinoma of the lung.
    Frytak S; Eagan RT; Creagan ET; Nichols WC
    Cancer Treat Rep; 1984 Sep; 68(9):1193-4. PubMed ID: 6478455
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II study of diaziquone in advanced soft tissue and bony sarcoma: a Southwest Oncology Group study.
    Zidar BL; Baker LH; Rivkin SE; Balcerzak SP; Stephens RL
    Cancer Treat Rep; 1985 Sep; 69(9):1035-6. PubMed ID: 4028037
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II study of aclarubicin in non-small cell lung cancer.
    Leiby JM; Hicks W; Roach RW; Neidhart JA
    Cancer Treat Rep; 1987 Mar; 71(3):323-4. PubMed ID: 3028622
    [No Abstract]   [Full Text] [Related]  

  • 6. Aclarubicin given as continuous infusion in non-small cell bronchogenic carcinoma.
    Chiuten DF; Umsawasdi T; Dhingra HM; Bodey GP; Valdivieso M
    Cancer Treat Rep; 1985 Nov; 69(11):1327-8. PubMed ID: 3867406
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma. A phase II study of the Southwest Oncology Group.
    Figlin RA; Crowley JJ; Jacobs EL; Muirhead M; Goodwin JW; Rinehart JJ; Livingston RB
    Cancer; 1996 Sep; 78(5):998-1003. PubMed ID: 8780537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitoxantrone for treatment of patients with refractory small cell carcinoma of the lung: a Southwest Oncology Group Study.
    Von Hoff DD; Chen T; Clark GM; Callahan SK; Livingston R
    Cancer Treat Rep; 1983 Apr; 67(4):403-4. PubMed ID: 6303588
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase I-II diaziquone chemotherapy in brain tumors.
    Madajewicz S; Spaulding M; Bhimani S; Avellanosa A; DeLos Santos R; Perry A; Zeigler P; Kirshner J
    Cancer Treat Rep; 1984 Jun; 68(6):913-4. PubMed ID: 6733706
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II evaluation of aclarubicin in lung cancer: a Southeastern Cancer Study Group Trial.
    Kramer BS; Birch R; Gockerman JP; Greco A; Prestridge K
    Cancer Treat Rep; 1986 Jun; 70(6):803-4. PubMed ID: 3015404
    [No Abstract]   [Full Text] [Related]  

  • 11. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
    Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line combination chemotherapy for advanced non-small cell lung cancer: the Eastern Cooperative Oncology Group and Southwest Oncology Group experience.
    Sandler A
    Semin Oncol; 1999 Oct; 26(5 Suppl 15):44-51. PubMed ID: 10566611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel and carboplatin in inoperable non-small cell lung cancer.
    Kosmidis P; Mylonakis N; Fountzilas G; Samantas E; Athanasiadis A; Skarlos D
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):68-70. PubMed ID: 9007126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer.
    von Pawel J; Wagner H; Niederle N; Heider A; Koschel G; Hecker D; Hanske M
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):47-50. PubMed ID: 9007121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46).
    Johnson DH; Paul DM; Hande KR; DeVore R
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):42-6. PubMed ID: 9007120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer and leukemia group B phase II non-small cell lung carcinoma trial: aziridinylbenzoquinone (AZQ).
    Carey RW; Comis RL; Anbar D; Kennedy BJ; Capizzi RL; Shulman P; Booth BW; Green M; Raich PC
    Cancer Treat Rep; 1983 Jan; 67(1):95-6. PubMed ID: 6616498
    [No Abstract]   [Full Text] [Related]  

  • 17. Cisplatin, doxorubicin, cyclophosphamide, lomustine, and vincristine (PACCO) in the treatment of non-small cell bronchogenic carcinoma.
    Whitehead RP; Rosenbaum PR; Carbone PP
    Cancer Treat Rep; 1984 May; 68(5):771-3. PubMed ID: 6539171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II clinical trial of diaziquone in bronchogenic carcinoma.
    Chiuten DF; Umsawasdi T; Dhingra HM; Murphy WK; Spitzer G; Carr DT; Bodey GP; Valdivieso M
    Cancer Treat Rep; 1985; 69(7-8):921-2. PubMed ID: 4016800
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase I-II study of the continuous infusion of doxorubicin in the treatment of non-small cell lung cancer.
    Green MD; Speyer JS; Bottino JC; Blum RH; Wernz JC; Muggia FM
    Cancer Treat Rep; 1984 Apr; 68(4):681-2. PubMed ID: 6713422
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer.
    Belani CP; Wang W; Johnson DH; Wagner H; Schiller J; Veeder M; Mehta M;
    J Clin Oncol; 2005 Jun; 23(16):3760-7. PubMed ID: 15837967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.